Efficacy and Safety of Tolvaptan in Japanese Patients With Acute Heart Failure
NCT ID: NCT01635517
Last Updated: 2017-06-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
274 participants
OBSERVATIONAL
2012-07-01
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure
NCT02352285
The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study
NCT01663662
Tolvaptan for Advanced or Refractory Heart Failure
NCT02959411
Regional Tolvaptan Registry
NCT02666651
A Study of HRS-9057 in Patients With Heart Failure and Volume Overload
NCT06506994
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tolvaptan
Tolvaptan administration
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. serum Na \< 140 mEq/L
3. age: \> or = 20 years at the time of informed consent
4. provided written informed consent.
Exclusion Criteria
2. patients with hypersensitivity to tolvaptan or similar compounds
3. anuric patients
4. patients who cannot feel thirst and are difficult to intake the fluid
5. patients who are pregnant, potentially pregnant or willing to be pregnant
6. patients have taken tolvaptan before enrollment after hospitalization
7. acute coronary syndrome
8. adrenal insufficiency
9. patients scheduled to undergo coronary angioplasty within the study period
10. ineligible patients according to the investigator's judgment
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nippon Medical School, Musashi Kosugi Hospital
UNKNOWN
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Naoki Sato, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Nippon Medical School, Musashi Kosugi Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nippon Medical School, Musashi Kosugi Hospital
Kawasaki, Kanagawa, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UMIN000008258
Identifier Type: REGISTRY
Identifier Source: secondary_id
TRIHF1203
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.